NIH’s 5 Biotech Funding Priorities in 2025 — and How You Can Position for

By Jenna Levenson, PhD, RN, MS

In a funding landscape that is increasingly competitive, staying attuned to the NIH’s evolving priorities is not just helpful—it is essential for biotech investigators looking to secure support. NIH’s 2025 strategic agenda focuses on high-impact science, equity in innovation, and real-world application. Here is what is topping the list—and how to position your biotech venture for success.

1. Advanced Therapeutics: Cell, Gene, and RNA-Based Therapies

NIH continues to double down on next-gen modalities. Funding is flowing into:

  • CRISPR/Cas technologies

  • mRNA/RNAi therapies

  • Cell-based regenerative solutions

How to position: Highlight scalability and safety validation early. Show clear translation from bench to bedside. Co-develop with academic labs for Phase I-readiness.

2. AI & Data-Driven Health Solutions

The NIH BRAIN Initiative and RADx programs are just the beginning. There is strong interest in:

  • AI in clinical trial optimization

  • Real-time biosensing and diagnostics

  • ML for drug repurposing

How to position: Use explainable models and reference FDA's AI/ML action plan. Show strong cross-functional collaboration—tech meets biomedicine.

3. Rare Diseases and Pediatric Innovation

Roughly 95% of rare diseases lack FDA-approved treatments. NIH supports platforms that can:

  • Accelerate diagnosis

  • Enable n-of-1 trial design

  • Build sustainable rare disease pipelines

How to position: Partner with patient advocacy groups (e.g., CTF, Global Genes). Embed patient voice into trial design from the outset.

4. Pandemic Preparedness & Biodefense

Emerging infectious diseases and biothreats remain top concerns. NIH is funding:

  • Rapid vaccine platforms

  • Long COVID research

  • Antiviral development & scalable manufacturing

How to position: Emphasize platform technologies that can pivot quickly. Highlight partnerships with BARDA, DOD, or global health orgs.

What Now?

To rise above the noise in 2025, biotech investigators must speak the NIH’s language. That means:

  • Building robust cross-disciplinary teams

  • Embedding real-world applicability

  • Thinking not just innovatively—but impactfully

Need help shaping a fundable proposal or navigating the NIH maze? Let’s talk.

Next
Next

What VCs Really Want (and How Biotech Startups Can Deliver)